---
figid: PMC6332919__SCIENTIFICA2018-5036213.001
figlink: /pmc/articles/PMC6332919/figure/fig1/
number: F1
caption: MAPK signalling pathway and its inhibitors.
pmcid: PMC6332919
papertitle: Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced
  Melanoma.
reftext: Irene Russo, et al. Scientifica (Cairo). 2018;2018:5036213.
pmc_ranked_result_index: '28847'
pathway_score: 0.9223481
filename: SCIENTIFICA2018-5036213.001.jpg
figtitle: MAPK signalling pathway and its inhibitors
year: '2018'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6332919__SCIENTIFICA2018-5036213.001.html
  '@type': Dataset
  description: MAPK signalling pathway and its inhibitors.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - BRAF
  - MAPK3
  - MAP2K1
  - MAPK1
  - MAP2K2
  - NRAS
  - Tyrosine
  - Vemurafenib
  - Dabrafenib
  - Trametinib
  - Cobimetinib
genes:
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: NRAS
  symbol: NRAS
  source: hgnc_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
chemicals:
- word: Tyrosine
  source: ''
  identifier: ''
- word: Vemurafenib
  source: MESH
  identifier: C551177
- word: Dabrafenib
  source: MESH
  identifier: C561627
- word: Trametinib
  source: MESH
  identifier: C560077
- word: Cobimetinib
  source: MESH
  identifier: C574276
diseases: []
figid_alias: PMC6332919__F1
redirect_from: /figures/PMC6332919__F1
figtype: Figure
---
